Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Diabetic Neuropathy Treatment Market

Diabetic Neuropathy Treatment Market Trends

Report ID: GMI10259
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Diabetic Neuropathy Treatment Market Trends

Recent advancements in the treatment and diagnosis of diabetic neuropathy have significantly contributed to the market growth. These innovations aim to enhance the efficacy of treatments, improve patient outcomes, and provide more precise treatment options and diagnostic tools.

Gene therapies targeting specific pathways involved in nerve damage are currently in development. These therapies aim to repair or replace defective genes, potentially reversing the damage caused by diabetic neuropathy?.
Additionally, new classes of drugs, such as sodium-glucose co-transporter-2 (SGLT2) inhibitors, are being investigated for their potential neuroprotective effects. These drugs not only help control blood sugar levels but also may offer benefits in reducing nerve damage.
Moreover, the development of targeted pain management drugs or therapies, such as monoclonal antibodies against nerve growth factor (NGF), shows promise for providing pain relief specifically for diabetic neuropathy patients.
As these new therapies become more widely available, they are likely to be adopted into standard practice, further driving market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global diabetic neuropathy treatment industry was valued at USD 4.3 billion in 2023 and is anticipated to register 7.9% CAGR between 2024 and 2032 due to the increasing prevalence of diabetes and advancements in therapeutic and diagnostic techniques.

The peripheral neuropathy segment in the diabetic neuropathy treatment market held 45.4% revenue share in 2023 due to its prevalence among diabetic patients and the availability of various therapeutic options, attracting both patients and health professionals.

Asia Pacific diabetic neuropathy treatment market accounted for USD 1.9 billion in 2023, driven by the high diabetes prevalence and increased awareness about early diagnosis and treatment of diabetic neuropathy.

Abbott, Boehringer Ingelheim GmbH, Eli Lilly and Company, Glenmark Pharmaceuticals Ltd, Janssen Pharmaceuticals, Inc, Lupin Pharmaceuticals, MEDA Pharma GmBH & Co. KG, and Pfizer Inc.